phase readout

NCT03319667: A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

ACTIVE_NOT_RECRUITINGupdated 1h ago

community read0 votes

Sponsor: Sanofi. Phase: PHASE3. Conditions: Plasma Cell Myeloma

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

last refreshed 1h ago

Found something off?